CD8A and neoplasm: In the same way, Burlion et al. recently reported, in humanized mice with breast tumors, that a combination of neutralizing anti-ICOS mAb and chemotherapy controls tumor growth by reducing the Treg proportion and increasing the CD8+ T cell/Treg ratio in the TME [164].